Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CASI Pharma Acquires HBV Treatment for China Use from Indian Pharma

publication date: Oct 23, 2018

CASI Pharma, a Maryland-Beijing biopharma, acquired a US FDA-approved abbreviated new drug application from Laurus Labs of India, for tenofovir disoproxil fumarate (TDF), a first-line treatment for hepatitis B. CASI will use the ANDA to apply for approval of the generic drug in China. China is home to 90 million people with HBV, one-third of the world's total. CASI will make upfront and milestone payments to Laurus, though details were not disclosed. More details....

Stock Symbol: (NSDQ: CASI)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.